11.61
price down icon0.77%   -0.09
after-market After Hours: 11.21 -0.40 -3.45%
loading
Eyepoint Pharmaceuticals Inc stock is traded at $11.61, with a volume of 414.57K. It is down -0.77% in the last 24 hours and up +34.53% over the past month. EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
See More
Previous Close:
$11.70
Open:
$11.53
24h Volume:
414.57K
Relative Volume:
0.58
Market Cap:
$791.27M
Revenue:
$46.02M
Net Income/Loss:
$-70.80M
P/E Ratio:
-4.117
EPS:
-2.82
Net Cash Flow:
$-1.61M
1W Performance:
+0.61%
1M Performance:
+34.53%
6M Performance:
-41.19%
1Y Performance:
+49.81%
1-Day Range:
Value
$11.06
$11.71
1-Week Range:
Value
$10.90
$12.47
52-Week Range:
Value
$5.855
$30.99

Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile

Name
Name
Eyepoint Pharmaceuticals Inc
Name
Phone
617-926-5000
Name
Address
480 PLEASANT STREET, WATERTOWN, MA
Name
Employee
144
Name
Twitter
@eyepointpharma
Name
Next Earnings Date
2024-11-08
Name
Latest SEC Filings
Name
EYPT's Discussions on Twitter

Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-22-24 Initiated JP Morgan Overweight
Nov-02-23 Initiated Mizuho Buy
Apr-21-23 Initiated Robert W. Baird Outperform
Jul-07-22 Initiated Chardan Capital Markets Buy
Mar-01-21 Initiated Cowen Outperform
Jan-28-21 Initiated Cantor Fitzgerald Overweight
Apr-06-20 Downgrade B. Riley FBR Buy → Neutral
Nov-04-19 Resumed Laidlaw Buy
Sep-12-19 Initiated Guggenheim Buy
View All

Eyepoint Pharmaceuticals Inc Stock (EYPT) Latest News

pulisher
06:33 AM

Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals - Scrip

06:33 AM
pulisher
05:10 AM

With 61% ownership, EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) boasts of strong institutional backing - Yahoo Finance

05:10 AM
pulisher
02:29 AM

Vanguard Group Inc's Strategic Acquisition in EyePoint Pharmaceu - GuruFocus.com

02:29 AM
pulisher
Nov 04, 2024

EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 5.4%Here's What Happened - MarketBeat

Nov 04, 2024
pulisher
Nov 04, 2024

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences - The Manila Times

Nov 04, 2024
pulisher
Nov 03, 2024

EyePoint Pharmaceuticals Announces Successful Closure of Underwritten Public Offering WATERTOWN, Mass., October 31, 2024 – EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) recently finalized its underwritten public offering of 14,636,363 shares - Defense World

Nov 03, 2024
pulisher
Nov 01, 2024

EYPTEyePoint Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan

Nov 01, 2024
pulisher
Nov 01, 2024

When (EYPT) Moves Investors should Listen - Stock Traders Daily

Nov 01, 2024
pulisher
Oct 31, 2024

EyePoint rises on interim data for mid-stage trial of its diabetic macular edema therapy - MSN

Oct 31, 2024
pulisher
Oct 31, 2024

EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares - The Manila Times

Oct 31, 2024
pulisher
Oct 30, 2024

EyePoint Pharmaceuticals prices $140M share offering - MSN

Oct 30, 2024
pulisher
Oct 30, 2024

EyePoint Pharmaceuticals (NASDAQ:EYPT) Sees Strong Trading VolumeWhat's Next? - MarketBeat

Oct 30, 2024
pulisher
Oct 30, 2024

EyePoint Pharmaceuticals (EYPT) Soars 27.6%: Is Further Upside Left in the Stock? - MSN

Oct 30, 2024
pulisher
Oct 29, 2024

Guggenheim maintains Buy on EyePoint with $68 target - Investing.com India

Oct 29, 2024
pulisher
Oct 29, 2024

EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering - The Manila Times

Oct 29, 2024
pulisher
Oct 29, 2024

EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering - GlobeNewswire Inc.

Oct 29, 2024
pulisher
Oct 29, 2024

EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 6.5%Should You Sell? - MarketBeat

Oct 29, 2024
pulisher
Oct 29, 2024

EyePoint launches $100 million public stock offering By Investing.com - Investing.com Australia

Oct 29, 2024
pulisher
Oct 29, 2024

EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Rating Reaffirmed by Chardan Capital - MarketBeat

Oct 29, 2024
pulisher
Oct 29, 2024

Revenues Not Telling The Story For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Shares Rise 52% - Simply Wall St

Oct 29, 2024
pulisher
Oct 29, 2024

‘Really competitive’ tax breaks keep EyePoint manufacturing in Mass. - The Business Journals

Oct 29, 2024
pulisher
Oct 29, 2024

PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - MSN

Oct 29, 2024
pulisher
Oct 29, 2024

Coinbase Global Inc Cl A (COIN-Q) QuotePress Release - The Globe and Mail

Oct 29, 2024
pulisher
Oct 29, 2024

HC Wainwright Reaffirms Buy Rating for EyePoint Pharmaceuticals (NASDAQ:EYPT) - Defense World

Oct 29, 2024
pulisher
Oct 29, 2024

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Consensus Rating of "Buy" from Analysts - MarketBeat

Oct 29, 2024
pulisher
Oct 28, 2024

EyePoint shares hold as analyst reiterates Buy rating By Investing.com - Investing.com South Africa

Oct 28, 2024
pulisher
Oct 28, 2024

EyePoint reports positive DURAVYU trial results for DME By Investing.com - Investing.com South Africa

Oct 28, 2024
pulisher
Oct 28, 2024

EyePoint launches $100 million public stock offering - Investing.com India

Oct 28, 2024
pulisher
Oct 28, 2024

EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock - The Manila Times

Oct 28, 2024
pulisher
Oct 28, 2024

Guggenheim maintains Buy on EyePoint with $68 target By Investing.com - Investing.com UK

Oct 28, 2024
pulisher
Oct 28, 2024

EyePoint reports positive DURAVYU trial results for DME - Investing.com India

Oct 28, 2024
pulisher
Oct 28, 2024

EyePoint shares hold as analyst reiterates Buy rating - Investing.com

Oct 28, 2024
pulisher
Oct 28, 2024

EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss - Yahoo Finance

Oct 28, 2024
pulisher
Oct 28, 2024

EyePoint Pharmaceuticals Shares Rise 35% on Positive Clinical Trial Data for Duravyu - MarketWatch

Oct 28, 2024
pulisher
Oct 28, 2024

EyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap UpHere's Why - MarketBeat

Oct 28, 2024
pulisher
Oct 28, 2024

EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema - The Manila Times

Oct 28, 2024
pulisher
Oct 26, 2024

EyePoint stock gains traction with new AMD trials, Jefferies sees 65% upside - Investing.com Canada

Oct 26, 2024
pulisher
Oct 26, 2024

EyePoint announces $175 million stock offering following record surge in share price - MSN

Oct 26, 2024
pulisher
Oct 25, 2024

Analyst Ratings For EyePoint Pharmaceuticals - Benzinga

Oct 25, 2024
pulisher
Oct 25, 2024

EyePoint stock gains traction with new AMD trials, Jefferies sees 65% upside By Investing.com - Investing.com South Africa

Oct 25, 2024
pulisher
Oct 25, 2024

EyePoint Pharmaceuticals (NASDAQ:EYPT) Given Buy Rating at HC Wainwright - MarketBeat

Oct 25, 2024
pulisher
Oct 25, 2024

SG Americas Securities LLC Sells 56,985 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - MarketBeat

Oct 25, 2024
pulisher
Oct 24, 2024

EyePoint begins Phase 3 trial for wet AMD treatment By Investing.com - Investing.com Australia

Oct 24, 2024
pulisher
Oct 24, 2024

Laidlaw keeps Buy rating, $50 target on EyePoint Pharmaceuticals - Investing.com

Oct 24, 2024
pulisher
Oct 24, 2024

Laidlaw keeps Buy rating, $50 target on EyePoint Pharmaceuticals By Investing.com - Investing.com Canada

Oct 24, 2024
pulisher
Oct 24, 2024

Alphabet Cl A (GOOGL-Q) QuotePress Release - The Globe and Mail

Oct 24, 2024
pulisher
Oct 24, 2024

EyePoint begins Phase 3 trial for wet AMD treatment - Investing.com

Oct 24, 2024
pulisher
Oct 24, 2024

EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration - StockTitan

Oct 24, 2024
pulisher
Oct 22, 2024

AAO 2024: EyePoint’s EYP-1901 proves non-inferiority to aflibercept in DAVIO 2 - Pharmaceutical Technology

Oct 22, 2024
pulisher
Oct 21, 2024

(EYPT) Investment Analysis and Advice - Stock Traders Daily

Oct 21, 2024

Eyepoint Pharmaceuticals Inc Stock (EYPT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Cap:     |  Volume (24h):